The role of chemotherapy in advanced thymoma

Jordan Schmitt, Patrick Loehrer

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Background: Thymoma and thymic carcinomas are rare malignancies. Most thymomas and about one-third of thymic carcinomas can be cured with local therapy. The remainder of will be candidates for systemic therapy. Numerous retrospective trials confirm objective responses to a variety of single-agent and combination chemotherapeutic regimens. Methods: No prospective randomized comparison of regimens has been performed because of the rarity of the disease. This paper reviewed the literature of chemotherapy in advanced thymic malignancies. Results: Existing data suggest that anthracycline plus cisplatin regimens seem to demonstrate higher response rates and perhaps longer median survival times compared with nonanthracycline-containing regimens. Discussion: Thymic malignancies are sensitive to a broad spectrum of systemic agents. Thymic carcinoma has a distinct clinical presentation and worse therapeutic outcomes than thymoma. Despite reproducible high response rates in thymoma, durable complete remissions are rare. Thus, novel new therapeutic targets need to be identified and appropriate agents developed to have further impact on this disease.

Original languageEnglish
JournalJournal of Thoracic Oncology
Volume5
Issue number10 SUPPL. 4
DOIs
StatePublished - Oct 2010

Fingerprint

Thymoma
Drug Therapy
Neoplasms
Anthracyclines
Therapeutics
Cisplatin

Keywords

  • Anthracycline
  • Cisplatin
  • Combination chemotherapy
  • Single agent therapy
  • Thymic carcinoma
  • Thymoma

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

The role of chemotherapy in advanced thymoma. / Schmitt, Jordan; Loehrer, Patrick.

In: Journal of Thoracic Oncology, Vol. 5, No. 10 SUPPL. 4, 10.2010.

Research output: Contribution to journalArticle

@article{f71ea3211c9c4a3e80fd59869494914d,
title = "The role of chemotherapy in advanced thymoma",
abstract = "Background: Thymoma and thymic carcinomas are rare malignancies. Most thymomas and about one-third of thymic carcinomas can be cured with local therapy. The remainder of will be candidates for systemic therapy. Numerous retrospective trials confirm objective responses to a variety of single-agent and combination chemotherapeutic regimens. Methods: No prospective randomized comparison of regimens has been performed because of the rarity of the disease. This paper reviewed the literature of chemotherapy in advanced thymic malignancies. Results: Existing data suggest that anthracycline plus cisplatin regimens seem to demonstrate higher response rates and perhaps longer median survival times compared with nonanthracycline-containing regimens. Discussion: Thymic malignancies are sensitive to a broad spectrum of systemic agents. Thymic carcinoma has a distinct clinical presentation and worse therapeutic outcomes than thymoma. Despite reproducible high response rates in thymoma, durable complete remissions are rare. Thus, novel new therapeutic targets need to be identified and appropriate agents developed to have further impact on this disease.",
keywords = "Anthracycline, Cisplatin, Combination chemotherapy, Single agent therapy, Thymic carcinoma, Thymoma",
author = "Jordan Schmitt and Patrick Loehrer",
year = "2010",
month = "10",
doi = "10.1097/JTO.0b013e3181f21129",
language = "English",
volume = "5",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "10 SUPPL. 4",

}

TY - JOUR

T1 - The role of chemotherapy in advanced thymoma

AU - Schmitt, Jordan

AU - Loehrer, Patrick

PY - 2010/10

Y1 - 2010/10

N2 - Background: Thymoma and thymic carcinomas are rare malignancies. Most thymomas and about one-third of thymic carcinomas can be cured with local therapy. The remainder of will be candidates for systemic therapy. Numerous retrospective trials confirm objective responses to a variety of single-agent and combination chemotherapeutic regimens. Methods: No prospective randomized comparison of regimens has been performed because of the rarity of the disease. This paper reviewed the literature of chemotherapy in advanced thymic malignancies. Results: Existing data suggest that anthracycline plus cisplatin regimens seem to demonstrate higher response rates and perhaps longer median survival times compared with nonanthracycline-containing regimens. Discussion: Thymic malignancies are sensitive to a broad spectrum of systemic agents. Thymic carcinoma has a distinct clinical presentation and worse therapeutic outcomes than thymoma. Despite reproducible high response rates in thymoma, durable complete remissions are rare. Thus, novel new therapeutic targets need to be identified and appropriate agents developed to have further impact on this disease.

AB - Background: Thymoma and thymic carcinomas are rare malignancies. Most thymomas and about one-third of thymic carcinomas can be cured with local therapy. The remainder of will be candidates for systemic therapy. Numerous retrospective trials confirm objective responses to a variety of single-agent and combination chemotherapeutic regimens. Methods: No prospective randomized comparison of regimens has been performed because of the rarity of the disease. This paper reviewed the literature of chemotherapy in advanced thymic malignancies. Results: Existing data suggest that anthracycline plus cisplatin regimens seem to demonstrate higher response rates and perhaps longer median survival times compared with nonanthracycline-containing regimens. Discussion: Thymic malignancies are sensitive to a broad spectrum of systemic agents. Thymic carcinoma has a distinct clinical presentation and worse therapeutic outcomes than thymoma. Despite reproducible high response rates in thymoma, durable complete remissions are rare. Thus, novel new therapeutic targets need to be identified and appropriate agents developed to have further impact on this disease.

KW - Anthracycline

KW - Cisplatin

KW - Combination chemotherapy

KW - Single agent therapy

KW - Thymic carcinoma

KW - Thymoma

UR - http://www.scopus.com/inward/record.url?scp=77957557420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957557420&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e3181f21129

DO - 10.1097/JTO.0b013e3181f21129

M3 - Article

VL - 5

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 10 SUPPL. 4

ER -